GuidelineThe Lancet. Oncology2013
Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.
Guideline in The Lancet. Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The application of mixed reality navigation system in robot-assisted radical prostatectomy for high-risk prostate cancer: a propensity score‑matched cohort study.Prostate cancer and prostatic diseases · 2026Article
- Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.Therapeutic advances in medical oncology · 2024Article
- Article
- Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017.BJU international · 2019Review
- The incidence, mortality, and risk factors of prostate cancer in Asian men.Prostate international · 2019Review
- Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand.BMC cancer · 2018Article
- Article
- Pharmacokinetic and pharmacodynamic comparison of subcutaneousTherapeutic advances in urology · 2018Article
- A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Erectile dysfunction and the risk of prostate cancer.Oncotarget · 2017Article
- Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.Current urology reports · 2016Review
- Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.Cell death & disease · 2016Article
- UICC International Session: What are the implications of sharing the concept of Universal Health Coverage for cancer in Asia?Cancer science · 2016Article
- Ten-year outcomes of I¹²⁵ low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan.World journal of urology · 2015Article
- Oncological outcomes following robotic-assisted radical prostatectomy in a multiracial Asian population.Journal of robotic surgery · 2015Article
- Evaluation of PSF1 as a prognostic biomarker for prostate cancer.Prostate cancer and prostatic diseases · 2015Article
- Effect of gyromagnetic fields on human prostatic adenocarcinoma cells.OncoTargets and therapy · 2015Article
- Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.Prostate international · 2014Article
- Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer.European journal of clinical pharmacology · 2014Review
- Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.Asian journal of andrologyArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many local and systemic options for prostate cancer have emerged in recent years, but existing management guidelines do not account for diversity in health resources between different countries. We present recommendations for the management of prostate cancer, stratified according to the extent of resource availability-based on a four-tier system of basic, limited, enhanced, and maximum resources-to enable applicability to Asian countries with differing levels of health-care resources. This statement of recommendations was formulated by a multidisciplinary panel from Asia-Pacific countries, at a consensus session on prostate cancer that was held as part of the 2013 Asian Oncology Summit in Bangkok, Thailand.
Indexed as
Identifiers
24176571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.